Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis.
KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0312563 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582929019043840 |
|---|---|
| author | Matthew D Gregory Kweku Ofosu-Asante Jassy Mary S Lazarte Pablo E Puente Nada Tawfeeq Nadine Belony Yong Huang Ite A Offringa Nazarius S Lamango |
| author_facet | Matthew D Gregory Kweku Ofosu-Asante Jassy Mary S Lazarte Pablo E Puente Nada Tawfeeq Nadine Belony Yong Huang Ite A Offringa Nazarius S Lamango |
| author_sort | Matthew D Gregory |
| collection | DOAJ |
| description | KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. Here we determine the effects of PCAIs on the viability, G-protein levels, downstream mediators, and apoptosis-related proteins on the KRAS-mutated, Black American-derived lung adenocarcinoma cell line, NCI-H23. Of the 17 PCAIs tested, compounds NSL-YHJ-2-27 and NSL-YHJ-2-46 showed the most potency with EC50 values of 2.7 and 3.3 μM, respectively. Western blotting was used to determine the effect of the PCAIs on the phosphorylation levels of MAPK pathway enzymes. After 48 h exposure to 5 μM of the PCAIs, NSL-YHJ-2-46, the MAPK proteins BRAF, MEK1/2, ERK1/2, and p90RSK were activated through phosphorylation by 90, 190, 150 and 120%, respectively. However, CRAF/RAF1 phosphorylation decreased by 40%, suggesting significant changes in the KRAS/MAPK signaling patterns. Furthermore, 5 μM of NSL-YHJ-2-27 depleted the singly polyisoprenylated monomeric G-proteins RAC 1/2/3 and CDC42 by 77 and 76%, respectively. The depletion of these key cytoskeletal proteins may account for the observed inhibition of cell migration and invasion, and spheroid invasion observed on exposure to NSL-YHJ-2-27 and NSL-YHJ-2-46. Treatment with 5 μM of NSL-YHJ-2-27 suppressed full-length inactive caspase 3 and 7 levels by 72 and 91%, respectively. An analysis of cells treated with the fluorescently labeled active caspase 3/7 irreversible inhibitor, CaspaTagTM Caspase-3/7 in situ reagent revealed a 124% increase in active caspase at 3 μM over controls. These findings clearly show the direct effects of the PCAIs on the RAS signaling pathway. Given the profound increases observed in RPS6KA1/p90RSK phosphorylation, future work will involve a determination whether the proapoptotic isoforms of RPS6KA1/p90RSK are phosphorylated due to the PCAIs treatments. These results support the potential use of the PCAIs as targeted therapies against cancers with KRAS mutations. |
| format | Article |
| id | doaj-art-162c4ca0528449b8afb30f6d38461cf8 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-162c4ca0528449b8afb30f6d38461cf82025-01-29T05:30:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-011910e031256310.1371/journal.pone.0312563Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis.Matthew D GregoryKweku Ofosu-AsanteJassy Mary S LazartePablo E PuenteNada TawfeeqNadine BelonyYong HuangIte A OffringaNazarius S LamangoKRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. Here we determine the effects of PCAIs on the viability, G-protein levels, downstream mediators, and apoptosis-related proteins on the KRAS-mutated, Black American-derived lung adenocarcinoma cell line, NCI-H23. Of the 17 PCAIs tested, compounds NSL-YHJ-2-27 and NSL-YHJ-2-46 showed the most potency with EC50 values of 2.7 and 3.3 μM, respectively. Western blotting was used to determine the effect of the PCAIs on the phosphorylation levels of MAPK pathway enzymes. After 48 h exposure to 5 μM of the PCAIs, NSL-YHJ-2-46, the MAPK proteins BRAF, MEK1/2, ERK1/2, and p90RSK were activated through phosphorylation by 90, 190, 150 and 120%, respectively. However, CRAF/RAF1 phosphorylation decreased by 40%, suggesting significant changes in the KRAS/MAPK signaling patterns. Furthermore, 5 μM of NSL-YHJ-2-27 depleted the singly polyisoprenylated monomeric G-proteins RAC 1/2/3 and CDC42 by 77 and 76%, respectively. The depletion of these key cytoskeletal proteins may account for the observed inhibition of cell migration and invasion, and spheroid invasion observed on exposure to NSL-YHJ-2-27 and NSL-YHJ-2-46. Treatment with 5 μM of NSL-YHJ-2-27 suppressed full-length inactive caspase 3 and 7 levels by 72 and 91%, respectively. An analysis of cells treated with the fluorescently labeled active caspase 3/7 irreversible inhibitor, CaspaTagTM Caspase-3/7 in situ reagent revealed a 124% increase in active caspase at 3 μM over controls. These findings clearly show the direct effects of the PCAIs on the RAS signaling pathway. Given the profound increases observed in RPS6KA1/p90RSK phosphorylation, future work will involve a determination whether the proapoptotic isoforms of RPS6KA1/p90RSK are phosphorylated due to the PCAIs treatments. These results support the potential use of the PCAIs as targeted therapies against cancers with KRAS mutations.https://doi.org/10.1371/journal.pone.0312563 |
| spellingShingle | Matthew D Gregory Kweku Ofosu-Asante Jassy Mary S Lazarte Pablo E Puente Nada Tawfeeq Nadine Belony Yong Huang Ite A Offringa Nazarius S Lamango Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. PLoS ONE |
| title | Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. |
| title_full | Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. |
| title_fullStr | Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. |
| title_full_unstemmed | Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. |
| title_short | Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. |
| title_sort | treatment of a mutant kras lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the mapk pathway inhibits cell migration and induces apoptosis |
| url | https://doi.org/10.1371/journal.pone.0312563 |
| work_keys_str_mv | AT matthewdgregory treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT kwekuofosuasante treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT jassymaryslazarte treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT pabloepuente treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT nadatawfeeq treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT nadinebelony treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT yonghuang treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT iteaoffringa treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis AT nazariusslamango treatmentofamutantkraslungcancercelllinewithpolyisoprenylatedcysteinylamideinhibitorsactivatesthemapkpathwayinhibitscellmigrationandinducesapoptosis |